FindTrial
Sign In

EC

DEVICE2 trials

Sponsors

GBG Forschungs GmbH, Lamiaa Khaled Zidan

Conditions

BRCA 1 /2 and / or HRDBreast CancerDiaphragm UltrasoundElectrical CardiometryHRpos Breast NeoplasmsNon Invasive Ventilation (NIV)RDS of PrematurityTriple Negative Breast Neoplasms

Phase 2

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency
CompletedNCT02789332
GBG Forschungs GmbHBRCA 1 /2 and / or HRD, Breast Cancer, HRpos Breast Neoplasms +1
Start: 2016-09-30End: 2020-02-29Updated: 2020-03-17

Unknown Phase

Diaphragmatic Ultrasound and Thoracic Fluid Content for Prediction of Non-Invasive Ventilation Failure in Neonates
CompletedNCT07148102
Lamiaa Khaled ZidanDiaphragm Ultrasound, Electrical Cardiometry, Non Invasive Ventilation (NIV) +1
Start: 2020-05-01End: 2023-05-01Updated: 2025-08-29

Related Papers

Diaphragmatic ultrasound and thoracic fluid content for prediction of non-invasive ventilation failure in neonates: a randomized controlled trial.
2025-12-09
Abstract P1-01-18: Prevalence of functional HRD by the RAD51 assay: a pooled analysis with 367 patients from BRCA-associated tumor types
Clinical Cancer Research2025-06-13
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study
Clinical Cancer Research2025-02-254 citations
Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study
Cancer Research2023-03-013 citations
Abstract P4-06-13: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study
Cancer Research2023-03-011 citations
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
2020-10-21110 citations
GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).
Journal of Clinical Oncology2019-05-2043 citations